Oxford BioMedica Broadens 5T4 Antibody Collaboration With Pfizer
— Diagnostic rights secured for Investigational New Drug application — Oxford, UK – 4 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announces Top-Line Results From Six Month Follow-Up of Third Patient Cohort in Prosavin® Phase I/II Study in Parkinson’s Disease
Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD) will be… Read More
Oxford BioMedica Board Changes
Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today announces that by mutual agreement, its Chairman, Dr Alan Kingsman, will leave the Board of Oxford BioMedica… Read More
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Stargardt Disease
— Second of four products in Phase I/II ocular programme partnered with sanofi-aventis approved to enter clinical development — Oxford, UK –… Read More
Oxford BioMedica Announces Publication of Trovax® Phase III Analyses in Cancer Immunology, Immunotherapy
— Immune Response Surrogate Algorithm Shown to be a Significant Predictor of Clinical Benefit — Oxford, UK – 15 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2010
Click here to download the full 2010 preliminary results statement.Click here to download the 2010 results slide deck.Click… Read More
Oxford BioMedica Appoints James Christie as New Head of Manufacturing
Oxford, UK – 9 February 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today announces the appointment of James Christie, BSc, MBA to the newly created role of Head of… Read More
Oxford BioMedica Acquires GMP Manufacturing Facility
— Support for Oxford BioMedica’s five LentiVector® technology-based programmes — — UK production facility in Oxford to… Read More
Results Of Firm Placing And Placing And Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION… Read More
Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More